Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion

Cancer Immunology, Immunotherapy

Volumn 56, Issue 4, 2007, Pages 573-580

  Brunstein, Flavia ^a   Hoving, Saske ^a   Aan De Wiel Ambagtsheer, Gisela ^a   De Bruijn, Ernst A ^b   Guetens, Gunther ^b,c   Eggermont, Alexander M M ^a   Ten Hagen, Timo L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Histamine; IL 2; Regional treatment; Sarcomas

Indexed keywords

HISTAMINE; INTERLEUKIN 2; MELPHALAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CONTROLLED STUDY; HISTOLOGY; LIMB PERFUSION; MALE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPILLARY PERMEABILITY; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DRUG SYNERGISM; HISTAMINE; HISTAMINE AGENTS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; MACROPHAGES; MALE; MELPHALAN; RATS; RATS, INBRED BN; RECOMBINANT PROTEINS; SARCOMA, EXPERIMENTAL;

EID: 33846830059     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0206-y     Document Type: Article

References (30)

1. Lienard D, Lejeune FJ, Ewalenko P (1992) In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 16:234-240
2. Eggermont AM, Schraffordt KH, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ (1996) Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for non-resectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14:2653-2665
3. Eggermont AM, Schraffordt KH, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224:756-764
4. Olieman AF, Lienard D, Eggermont AM, Kroon BB, Lejeune FJ, Hoekstra HJ, Koops HS (1999) Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study. Arch Surg 134:303-307
5. Eggermont AM, de Wilt JH, ten Hagen TL (2003) Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 4:429-437
6. de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM (2000) Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 82:1000-1003
7. de Wilt JH, Manusama ER, van Tiel ST, van IJken MG, ten Hagen TL, Eggermont AM (1999). Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 80:161-166
8. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL (2000) TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 82:973-980
9. van Etten B, de Vries MR, van IJken MG, Lans TE, Guetens G, Ambagtsheer G, van Tiel ST, de Boeck G, de Bruijn EA, Eggermont AM, ten Hagen TL (2003) Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer 88:314-319
10. van Ijken MGA, van Etten B, de Wilt JHW, van Tiel ST, ten Hagen TLM, Eggermont AMM (2000) TNF-alpha augments anti-tumor efficacy in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother 23:449-455
11. Garrison JC (1990) Histamine, bradykinin, 5-hydroxytryptamine and their antagonists. In: Gilman AG, Rall TW, Nie AS, Taylor P (eds) The pharmacological basis of therapeutics. 8th edn, Pergamon, Elmsford, pp 575-599
12. Brunstein F, Hoving S, Seynhaeve AL, van Tiel ST, Guetens G, de Bruijn EA, Eggermont AM, ten Hagen TL (2004) Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion - preclinical studies. J Natl Cancer Inst 96:1603-1610
13. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA (2003) Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 95:741-749
14. Siegel JP, Puri RK (1991) Interleukin-2 toxicity. J Clin Oncol 9(4):694-704
15. Hoving S, Brunstein F, aan de Wiel Ambagtsheer G, van Tiel ST, de Boeck G, de Bruijn EA, Eggermont AM, ten Hagen TL (2005) Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 65:4300-4308
16. Winkelhake JL, Gauny SS (1990) Human recombinant interleukin-2 as an experimental therapeutic. Pharmacol Rev 42(1):1-28
17. Naredi P (2002) Histamine as an adjunct to immunotherapy. Semin Oncol 29:31-34
18. Hellstrand K (2002) Histamine in cancer immunotherapy: a preclinical background. Semin Oncol 29:35-40
19. Kort WJ, Zondervan PE, Hulsman LO, Weijma IM, Westbroek DL (1984) Incidence of spontaneous tumors in a group of retired breeder female brown Norway rats. J Natl Cancer Inst 72:709-713
20. de Boeck G, van Cauwenberghe K, Eggermont AM, van Oosterom AT, de Bruijn EA (1997) Determination of melphalan and hydrolysis products in body Xuids by GC-MS. J High Res Chromatogr 20:697-700
21. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
22. Jaffe EA, Nachman RL, Becker CG, Minick R (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52:2745-2756
23. Asea A, Hermodsson S, Hellstrand K (1996) Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scand J Immunol 43:9-15
24. Azuma Y, Shinohara M, Wang PL, Hidaka A, Ohura K (2001) Histamine inhibits chemotaxis, phagocytosis, superoxide anion production, and the production of TNFalpha and IL-12 by macrophages via H2-receptors. Int Immunopharmacol 1:1867-1875
25. Hayley S, Kelly O, Anisman H (2002) Murine tumor necrosis factor-alpha sensitizes plasma corticosterone activity and the manifestation of shock: modulation by histamine. J Neuroimmunol 131:60-69
26. Wang J, Al-Lamki RS, Zhang H, Kirkiles-Smith N, Gaeta ML, Thiru S, Pober JS, Bradley JR (2005) Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. J Biol Chem 278:21751-21760
27. Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, Meijer S, van der Sijp JRM, Beelen RHJ, van Egmond M (2005) Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol 207:147-155
28. Klimp AH, de Vries EGE, Scherphof GL, Daemen T (2002) A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol 44:143-161
29. Agarwala SS, Sabbagh MH (2001) Histamine dihydrochloride: inhibiting oxidants and synergising IL-2 mediated immune activation in the tumour microenvironment. Expert Opin Biol Ther 1(5):869-879
30. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA (2003) Identification of a protein fragment of Interleukin-2 responsible for vasopermeability. J Natl Cancer Inst 95:741-749